Hims & Hers Health, Inc.·4

May 22, 4:16 PM ET

Carroll Patrick Harrison 4

4 · Hims & Hers Health, Inc. · Filed May 22, 2026

Research Summary

AI-generated summary of this filing

Updated

Hims & Hers (HIMS) CMO Patrick Harrison Receives 435 RSU Award

What Happened
Patrick Harrison, Chief Medical Officer and director of Hims & Hers Health, Inc. (HIMS), received a grant of 435 Restricted Stock Units (RSUs) on 2026-05-20. The RSUs were granted at a notional grant price of $22.98 and were issued in lieu of a $10,000 cash director retainer fee (435 = $10,000 / $22.98). These RSUs are a derivative award that convert into one share of Class A common stock per RSU upon vesting; they will vest in full on the company’s next quarterly vesting date.

Key Details

  • Transaction date: 2026-05-20; reported on Form 4 filed 2026-05-22. No late filing flag indicated.
  • Grant type/code: Award/Grant (derivative RSUs), 435 RSUs, grant price used $22.98 (cash-equivalent ≈ $10,000).
  • Economic nature: RSUs are a contingent right to receive one share per RSU upon vesting (see footnote F1).
  • Reason: Issued under the Issuer’s Director Compensation Policy in lieu of the Q1 2026 cash retainer (footnote F2).
  • Shares owned after transaction: Not specified in the provided filing details.

Context
This is a routine director compensation award (deferred fees converted into RSUs), not a market purchase or sale. Because RSUs only convert to actual shares when they vest, this grant does not represent an immediate buy or sell of stock but compensates the director in equity tied to future vesting.

Insider Transaction Report

Form 4
Period: 2026-05-20
Carroll Patrick Harrison
Chief Medical Officer
Transactions
  • Award

    Restricted Stock Unit

    [F1][F2]
    2026-05-20+435435 total
    From: 2026-06-15Class A Common Stock (435 underlying)
Footnotes (2)
  • [F1]The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU.
  • [F2]The RSUs were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy, in lieu of the director retainer fee for the first quarter of 2026. The number of RSUs granted was calculated by dividing the foregone cash fees of $10,000 by the grant price of $22.98. The RSUs will vest in full on the Company's next quarterly vesting date.
Signature
/s/ Kimberly Mather, Attorney-in-Fact for Patrick Harrison Carroll|2026-05-22

Documents

1 file
  • 4
    wk-form4_1779480976.xmlPrimary

    FORM 4